Jennifer Wu, MD

  • Specialties: Medical Oncology, Hematology
  • Language: English

About Me

I was first drawn to medicine because I wanted to help people. I chose hematology and oncology because they are rapidly evolving fields—through their advances, I can treat people using the newest therapies. More importantly, I can care for people by forging meaningful relationships with them.

I treat each patient as a partner, and together, we work toward a common goal. Communication with my patients and their caregivers is essential to providing the best care. I also prioritize providing my patients with access to clinical trials.

At Perlmutter Cancer Center, my colleagues and I approach cancer treatment as a collaboration between specialties. We offer patients the most current clinical trials and we strive to provide as much support as possible for patients and families during such a difficult time.

My clinical and research interest is gastrointestinal cancers, with a focus on liver and biliary cancer, pancreatic cancer, and gastric cancer. Currently, I am studying whether radiation therapy in combination with immunotherapy is an effective treatment for pancreatic cancer.


Conditions and Treatments

gastrointestinal cancer, colon cancer, rectal cancer, pancreatic cancer, esophageal cancer, stomach cancer, anal cancer, gallbladder cancer, biliary cancer, liver cancer, abdominal tumor, colorectal cancer
Show More Conditions

Credentials

Positions
  • Associate Professor, Department of Medicine
  • Section Chief, Hematology and Medical Oncology, Bellevue Hospital
  • Director, Bellevue Cancer Center
Board Certifications
  • American Board of Internal Medicine (Hematology), 2007
  • American Board of Internal Medicine (Medical Oncology), 2006
  • American Board of Internal Medicine - Internal Medicine, 2003
Education and Training
  • Fellowship, NYU Medical Center, Hematology/Oncology, 2006
  • Fellowship, NYU Medical Center, Hematology/Oncology, 2004
  • MD from Albert Einstein College of Med, 2000
Departments

Is this your profile?

Edit profile

Is this your profile?

Edit profile

Clinical Trials and Research Studies

  • A Phase 3 Randomized Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

    Learn More
  • A PHASE III OPEN-LABEL RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

    Learn More
  • A PHASE l/ll OPEN LABEL MULTI-CENTER STUDY OF IMMUNE CHECKPOINT THERAPY WITH NIVOLUMAB FOR PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA

    Learn More
View All Research Studies (28)

Publications

Read All Publications (28)